BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ. Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol 2014;13:461-71. [PMID: 24680372 DOI: 10.1016/S1474-4422(14)70053-5] [Cited by in Crossref: 183] [Cited by in F6Publishing: 60] [Article Influence: 22.9] [Reference Citation Analysis]
Number Citing Articles
1 Hoyer D, Jacobson LH. Orexin Receptor Antagonists. Curr Sleep Medicine Rep 2017;3:342-53. [DOI: 10.1007/s40675-017-0099-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Jacobson LH, Hoyer D, de Lecea L. Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med 2022. [PMID: 35043499 DOI: 10.1111/joim.13406] [Reference Citation Analysis]
3 Neylan TC, Richards A, Metzler TJ, Ruoff LM, Varbel J, O'Donovan A, Sivasubramanian M, Motraghi T, Hlavin J, Batki SL, Inslicht SS, Samuelson K, Morairty SR, Kilduff TS. Acute cognitive effects of the hypocretin receptor antagonist almorexant relative to zolpidem and placebo: a randomized clinical trial. Sleep 2020;43:zsaa080. [PMID: 32303763 DOI: 10.1093/sleep/zsaa080] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
4 Izuhara M, Miura S, Otsuki K, Nagahama M, Hayashida M, Hashioka S, Asou H, Kitagaki H, Inagaki M. Magnetic Resonance Spectroscopy in the Ventral Tegmental Area Distinguishes Responders to Suvorexant Prior to Treatment: A 4-Week Prospective Cohort Study. Front Psychiatry 2021;12:714376. [PMID: 34497544 DOI: 10.3389/fpsyt.2021.714376] [Reference Citation Analysis]
5 Gotter AL, Garson SL, Stevens J, Munden RL, Fox SV, Tannenbaum PL, Yao L, Kuduk SD, McDonald T, Uslaner JM, Tye SJ, Coleman PJ, Winrow CJ, Renger JJ. Differential sleep-promoting effects of dual orexin receptor antagonists and GABAA receptor modulators. BMC Neurosci 2014;15:109. [PMID: 25242351 DOI: 10.1186/1471-2202-15-109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
6 Kishi T, Matsunaga S, Iwata N. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. PLoS One 2015;10:e0136910. [PMID: 26317363 DOI: 10.1371/journal.pone.0136910] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
7 Kale HP, Qureshi ZP, Shah R, Khandker R, Botteman M, Meng W, Benca R. Changes in Healthcare Resource Use and Costs in Commercially Insured Insomnia Patients Initiating Suvorexant. Adv Ther 2021;38:5221-37. [PMID: 34463922 DOI: 10.1007/s12325-021-01891-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Suvorexant in Patients with Insomnia: Pooled Analyses of Three-Month Data from Phase-3 Randomized Controlled Clinical Trials. J Clin Sleep Med 2016;12:1215-25. [PMID: 27397664 DOI: 10.5664/jcsm.6116] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
9 Herring WJ, Connor KM, Snyder E, Snavely DB, Zhang Y, Hutzelmann J, Matzura-Wolfe D, Benca RM, Krystal AD, Walsh JK, Lines C, Roth T, Michelson D. Clinical profile of suvorexant for the treatment of insomnia over 3 months in women and men: subgroup analysis of pooled phase-3 data. Psychopharmacology (Berl) 2017;234:1703-11. [PMID: 28265715 DOI: 10.1007/s00213-017-4573-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
10 Li F, Li S, Liu Y, Cao K, Yang M. Effect of Heweianshen Decoction on Orexin-A and Cholecystokinin-8 Expression in Rat Models of Insomnia. Evid Based Complement Alternat Med 2016;2016:8034263. [PMID: 27688792 DOI: 10.1155/2016/8034263] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
11 Connor KM, Mahoney E, Jackson S, Hutzelmann J, Zhao X, Jia N, Snyder E, Snavely D, Michelson D, Roth T, Herring WJ. A Phase II Dose-Ranging Study Evaluating the Efficacy and Safety of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Primary Insomnia. Int J Neuropsychopharmacol 2016;19:pyw022. [PMID: 26979830 DOI: 10.1093/ijnp/pyw022] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
12 Anderson KN. An update in sleep neurology: the latest bedtime stories. J Neurol 2015;262:487-91. [PMID: 25491077 DOI: 10.1007/s00415-014-7602-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
13 Hoyer D, Allen A, Jacobson LH. Hypnotics with novel modes of action. Br J Clin Pharmacol 2020;86:244-9. [PMID: 31756268 DOI: 10.1111/bcp.14180] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
14 Iqbal M, Ezzeldin E, Khalil NY, Al-Rashood ST, Al-Rashood KA. Simple and Highly Sensitive UPLC-ESI-MS/MS Assay for Rapid Determination of Suvorexant in Plasma. J Anal Toxicol 2017;41:114-20. [PMID: 28376227 DOI: 10.1093/jat/bkw111] [Reference Citation Analysis]
15 Krystal AD, Prather AA, Ashbrook LH. The assessment and management of insomnia: an update. World Psychiatry 2019;18:337-52. [PMID: 31496087 DOI: 10.1002/wps.20674] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 9.3] [Reference Citation Analysis]
16 Landry I, Nakai K, Ferry J, Aluri J, Hall N, Lalovic B, Moline ML. Pharmacokinetics, Pharmacodynamics, and Safety of the Dual Orexin Receptor Antagonist Lemborexant: Findings From Single-Dose and Multiple-Ascending-Dose Phase 1 Studies in Healthy Adults. Clin Pharmacol Drug Dev 2021;10:153-65. [PMID: 32468649 DOI: 10.1002/cpdd.817] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
17 Connor KM, Ceesay P, Hutzelmann J, Snavely D, Krystal AD, Trivedi MH, Thase M, Lines C, Herring WJ, Michelson D. Phase II Proof-of-Concept Trial of the Orexin Receptor Antagonist Filorexant (MK-6096) in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol 2017;20:613-8. [PMID: 28582570 DOI: 10.1093/ijnp/pyx033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
18 Simmons SJ, Gentile TA. Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect. Brain Res 2020;1731:146164. [PMID: 30796894 DOI: 10.1016/j.brainres.2019.02.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kärppä M, Yardley J, Pinner K, Filippov G, Zammit G, Moline M, Perdomo C, Inoue Y, Ishikawa K, Kubota N. Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep 2020;43:zsaa123. [PMID: 32585700 DOI: 10.1093/sleep/zsaa123] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 23.0] [Reference Citation Analysis]
20 Sieminski M, Szypenbejl J, Partinen E. Orexins, Sleep, and Blood Pressure. Curr Hypertens Rep. 2018;20:79. [PMID: 29992504 DOI: 10.1007/s11906-018-0879-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
21 Janto K, Prichard JR, Pusalavidyasagar S. An Update on Dual Orexin Receptor Antagonists and Their Potential Role in Insomnia Therapeutics. J Clin Sleep Med 2018;14:1399-408. [PMID: 30092886 DOI: 10.5664/jcsm.7282] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 6.8] [Reference Citation Analysis]
22 Han Y, Yuan K, Zheng Y, Lu L. Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders. Neurosci Bull 2020;36:432-48. [PMID: 31782044 DOI: 10.1007/s12264-019-00447-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
23 Norman JL, Anderson SL. Novel class of medications, orexin receptor antagonists, in the treatment of insomnia - critical appraisal of suvorexant. Nat Sci Sleep. 2016;8:239-247. [PMID: 27471419 DOI: 10.2147/nss.s76910] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
24 Sandsmark DK, Elliott JE, Lim MM. Sleep-Wake Disturbances After Traumatic Brain Injury: Synthesis of Human and Animal Studies. Sleep 2017;40. [PMID: 28329120 DOI: 10.1093/sleep/zsx044] [Cited by in Crossref: 32] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
25 Drake CL, Kalmbach DA, Cheng P, Roth T, Tran KM, Cuamatzi-Castelan A, Atkinson R, Singh M, Tonnu CV, Fellman-Couture C. Can the Orexin Antagonist Suvorexant Preserve the Ability to Awaken to Auditory Stimuli While Improving Sleep? J Clin Sleep Med 2019;15:1285-91. [PMID: 31538599 DOI: 10.5664/jcsm.7920] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Ishibashi Y, Nishitani R, Shimura A, Takeuchi A, Touko M, Kato T, Chiba S, Ashidate K, Ishiwata N, Ichijo T, Sasabe M. Non-GABA sleep medications, suvorexant as risk factors for falls: Case-control and case-crossover study. PLoS One 2020;15:e0238723. [PMID: 32916693 DOI: 10.1371/journal.pone.0238723] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
27 Asnis GM, Thomas M, Henderson MA. Pharmacotherapy Treatment Options for Insomnia: A Primer for Clinicians. Int J Mol Sci 2015;17:E50. [PMID: 26729104 DOI: 10.3390/ijms17010050] [Cited by in Crossref: 41] [Cited by in F6Publishing: 26] [Article Influence: 5.9] [Reference Citation Analysis]
28 Krystal AD. New Developments in Insomnia Medications of Relevance to Mental Health Disorders. Psychiatr Clin North Am 2015;38:843-60. [PMID: 26600112 DOI: 10.1016/j.psc.2015.08.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
29 Pillai V, Roth T, Roehrs T, Moss K, Peterson EL, Drake CL. Effectiveness of Benzodiazepine Receptor Agonists in the Treatment of Insomnia: An Examination of Response and Remission Rates. Sleep 2017;40. [PMID: 28364510 DOI: 10.1093/sleep/zsw044] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
30 Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ. Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects. Sleep 2014;37:1609-19. [PMID: 25197807 DOI: 10.5665/sleep.4068] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
31 Kram DE, Krasnow SM, Levasseur PR, Zhu X, Stork LC, Marks DL. Dexamethasone Chemotherapy Does Not Disrupt Orexin Signaling. PLoS One 2016;11:e0168731. [PMID: 27997622 DOI: 10.1371/journal.pone.0168731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
32 Roth T, Rosenberg R, Morin CM, Yardley J, Pinner K, Perdomo C, Atkins N, Pappadopulos E, Malhotra M, Moline M. Impact of lemborexant treatment on insomnia severity: analyses from a 12-month study of adults with insomnia disorder. Sleep Medicine 2022. [DOI: 10.1016/j.sleep.2022.01.024] [Reference Citation Analysis]
33 Voysey ZJ, Barker RA, Lazar AS. The Treatment of Sleep Dysfunction in Neurodegenerative Disorders. Neurotherapeutics 2021;18:202-16. [PMID: 33179197 DOI: 10.1007/s13311-020-00959-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
34 Ascher K, Abreu AR, Chediak AD. Management of Insomnia in Chronic Lung Diseases. Curr Pulmonol Rep 2020;9:102-9. [DOI: 10.1007/s13665-020-00253-z] [Reference Citation Analysis]
35 Dubey AK, Handu SS, Mediratta PK. Suvorexant: The first orexin receptor antagonist to treat insomnia. J Pharmacol Pharmacother 2015;6:118-21. [PMID: 25969666 DOI: 10.4103/0976-500X.155496] [Cited by in Crossref: 36] [Cited by in F6Publishing: 10] [Article Influence: 5.1] [Reference Citation Analysis]
36 Vermeeren A, Sun H, Vuurman EF, Jongen S, Van Leeuwen CJ, Van Oers AC, Palcza J, Li X, Laethem T, Heirman I, Bautmans A, Troyer MD, Wrishko R, McCrea J. On-the-Road Driving Performance the Morning after Bedtime Use of Suvorexant 20 and 40 mg: A Study in Non-Elderly Healthy Volunteers. Sleep 2015;38:1803-13. [PMID: 26039969 DOI: 10.5665/sleep.5168] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
37 Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong Q, Giorgi L, Satlin A. Lemborexant, A Dual Orexin Receptor Antagonist (DORA) for the Treatment of Insomnia Disorder: Results From a Bayesian, Adaptive, Randomized, Double-Blind, Placebo-Controlled Study. J Clin Sleep Med 2017;13:1289-99. [PMID: 29065953 DOI: 10.5664/jcsm.6800] [Cited by in Crossref: 50] [Cited by in F6Publishing: 43] [Article Influence: 10.0] [Reference Citation Analysis]
38 Keks NA, Hope J. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders? Australas Psychiatry 2022;:10398562221092310. [PMID: 35491942 DOI: 10.1177/10398562221092310] [Reference Citation Analysis]
39 Shiga T, Hoshino H, Ochiai H, Osakabe Y, Kanno K, Horikoshi S, Miura I, Yabe H. Effects of benzodiazepine and orexin receptor antagonist on cognitive function revealed by auditory event-related potentials. J Psychopharmacol 2021;35:1488-95. [PMID: 34330170 DOI: 10.1177/02698811211035390] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Roch C, Bergamini G, Steiner MA, Clozel M. Nonclinical pharmacology of daridorexant: a new dual orexin receptor antagonist for the treatment of insomnia. Psychopharmacology (Berl) 2021;238:2693-708. [PMID: 34415378 DOI: 10.1007/s00213-021-05954-0] [Reference Citation Analysis]
41 De Crescenzo F, Foti F, Ciabattini M, Del Giovane C, Watanabe N, Sañé Schepisi M, Quested DJ, Cipriani A, Barbui C, Amato L; Cochrane Common Mental Disorders Group. Comparative efficacy and acceptability of pharmacological treatments for insomnia in adults: a systematic review and network meta-analysis. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd012364] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Nakamura F, Kuribayashi S, Tanaka F, Kawami N, Fujiwara Y, Iwakiri K, Kusano M, Uraoka T. Impact of improvement of sleep disturbance on symptoms and quality of life in patients with functional dyspepsia. BMC Gastroenterol 2021;21:78. [PMID: 33602148 DOI: 10.1186/s12876-021-01659-y] [Reference Citation Analysis]
43 Tampi RR, Manikkara G, Balachandran S, Taparia P, Hrisko S, Srinivasan S, Tampi DJ. Suvorexant for insomnia in older adults: a perspective review. Drugs Context 2018;7:212517. [PMID: 29445409 DOI: 10.7573/dic.212517] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
44 Sano H, Asai Y, Miyazaki M, Iwakura M, Maeda Y, Hara M. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey. Expert Opin Drug Saf 2019;18:1109-18. [PMID: 31478753 DOI: 10.1080/14740338.2019.1657091] [Reference Citation Analysis]
45 Hirano A, Hsu PK, Zhang L, Xing L, McMahon T, Yamazaki M, Ptáček LJ, Fu YH. DEC2 modulates orexin expression and regulates sleep. Proc Natl Acad Sci U S A 2018;115:3434-9. [PMID: 29531056 DOI: 10.1073/pnas.1801693115] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
46 Uslaner JM, Herring WJ, Coleman PJ. The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts. ACS Pharmacol Transl Sci 2020;3:161-8. [PMID: 32259095 DOI: 10.1021/acsptsci.9b00110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Chow M, Cao M. The hypocretin/orexin system in sleep disorders: preclinical insights and clinical progress. Nat Sci Sleep 2016;8:81-6. [PMID: 27051324 DOI: 10.2147/NSS.S76711] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
48 Nixon JP, Mavanji V, Butterick TA, Billington CJ, Kotz CM, Teske JA. Sleep disorders, obesity, and aging: the role of orexin. Ageing Res Rev 2015;20:63-73. [PMID: 25462194 DOI: 10.1016/j.arr.2014.11.001] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]
49 Hamidovic A. Dual Orexin Receptor Antagonists (DORAs) as an Adjunct Treatment for Smoking Cessation. CNS Drugs 2022. [PMID: 35451800 DOI: 10.1007/s40263-022-00918-0] [Reference Citation Analysis]
50 Herring WJ, Ceesay P, Snyder E, Bliwise D, Budd K, Hutzelmann J, Stevens J, Lines C, Michelson D. Polysomnographic assessment of suvorexant in patients with probable Alzheimer's disease dementia and insomnia: a randomized trial. Alzheimers Dement 2020;16:541-51. [PMID: 31944580 DOI: 10.1002/alz.12035] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
51 James MH, Mahler SV, Moorman DE, Aston-Jones G. A Decade of Orexin/Hypocretin and Addiction: Where Are We Now? Curr Top Behav Neurosci 2017;33:247-81. [PMID: 28012090 DOI: 10.1007/7854_2016_57] [Cited by in Crossref: 80] [Cited by in F6Publishing: 76] [Article Influence: 16.0] [Reference Citation Analysis]
52 Lee-Iannotti JK, Parish JM. Suvorexant: a promising, novel treatment for insomnia. Neuropsychiatr Dis Treat 2016;12:491-5. [PMID: 26955275 DOI: 10.2147/NDT.S31495] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
53 Rhyne DN, Anderson SL. Suvorexant in insomnia: efficacy, safety and place in therapy. Ther Adv Drug Saf 2015;6:189-95. [PMID: 26478806 DOI: 10.1177/2042098615595359] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
54 Li SB, Jones JR, de Lecea L. Hypocretins, Neural Systems, Physiology, and Psychiatric Disorders. Curr Psychiatry Rep 2016;18:7. [PMID: 26733323 DOI: 10.1007/s11920-015-0639-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
55 So M, Hashimoto H, Saito R, Yamamoto Y, Motojima Y, Ueno H, Sonoda S, Yoshimura M, Maruyama T, Kusuhara K, Ueta Y. Inhibition of ghrelin-induced feeding in rats by pretreatment with a novel dual orexin receptor antagonist. J Physiol Sci 2018;68:129-36. [PMID: 28054308 DOI: 10.1007/s12576-016-0517-5] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
56 Hatano M, Kamei H, Inagaki R, Matsuzaki H, Hanya M, Yamada S, Iwata N. Assessment of Switching to Suvorexant versus the Use of Add-on Suvorexant in Combination with Benzodiazepine Receptor Agonists in Insomnia Patients: A Retrospective Study. Clin Psychopharmacol Neurosci 2018;16:184-9. [PMID: 29739132 DOI: 10.9758/cpn.2018.16.2.184] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
57 Sun H, Palcza J, Card D, Gipson A, Rosenberg R, Kryger M, Lines C, Wagner JA, Troyer MD. Effects of Suvorexant, an Orexin Receptor Antagonist, on Respiration during Sleep In Patients with Obstructive Sleep Apnea. J Clin Sleep Med 2016;12:9-17. [PMID: 26194728 DOI: 10.5664/jcsm.5382] [Cited by in Crossref: 23] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
58 Ek J, Jacobs W, Kaylor B, McCall WV. Addiction and Sleep Disorders. Adv Exp Med Biol 2021;1297:163-71. [PMID: 33537944 DOI: 10.1007/978-3-030-61663-2_12] [Reference Citation Analysis]
59 Braley TJ, Chervin RD. A practical approach to the diagnosis and management of sleep disorders in patients with multiple sclerosis. Ther Adv Neurol Disord 2015;8:294-310. [PMID: 26600873 DOI: 10.1177/1756285615605698] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
60 Tian Y, Qin Z, Han Y. Suvorexant with or without ramelteon to prevent delirium: a systematic review and meta-analysis. Psychogeriatrics 2021. [PMID: 34881812 DOI: 10.1111/psyg.12792] [Reference Citation Analysis]
61 Petrous J, Furmaga K. Adverse reaction with suvorexant for insomnia: acute worsening of depression with emergence of suicidal thoughts. BMJ Case Rep 2017;2017:bcr-2017-222037. [PMID: 29066641 DOI: 10.1136/bcr-2017-222037] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
62 Borniger JC, Walker Ii WH, Surbhi, Emmer KM, Zhang N, Zalenski AA, Muscarella SL, Fitzgerald JA, Smith AN, Braam CJ, TinKai T, Magalang UJ, Lustberg MB, Nelson RJ, DeVries AC. A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast Cancer. Cell Metab 2018;28:118-129.e5. [PMID: 29805100 DOI: 10.1016/j.cmet.2018.04.021] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
63 Vermeeren A, Vets E, Vuurman EF, Van Oers AC, Jongen S, Laethem T, Heirman I, Bautmans A, Palcza J, Li X, Troyer MD, Wrishko R, McCrea J, Sun H. On-the-road driving performance the morning after bedtime use of suvorexant 15 and 30 mg in healthy elderly. Psychopharmacology (Berl) 2016;233:3341-51. [PMID: 27424295 DOI: 10.1007/s00213-016-4375-x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
64 Porwal A, Yadav YC, Pathak K, Yadav R. An Update on Assessment, Therapeutic Management, and Patents on Insomnia. Biomed Res Int 2021;2021:6068952. [PMID: 34708126 DOI: 10.1155/2021/6068952] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Urrestarazu E, Iriarte J. Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies. Nat Sci Sleep 2016;8:21-33. [PMID: 26834500 DOI: 10.2147/NSS.S76706] [Cited by in Crossref: 48] [Cited by in F6Publishing: 27] [Article Influence: 8.0] [Reference Citation Analysis]
66 Rosenberg R, Citrome L, Drake CL. Advances in the Treatment of Chronic Insomnia: A Narrative Review of New Nonpharmacologic and Pharmacologic Therapies. Neuropsychiatr Dis Treat 2021;17:2549-66. [PMID: 34393484 DOI: 10.2147/NDT.S297504] [Reference Citation Analysis]
67 Gotter AL, Forman MS, Harrell CM, Stevens J, Svetnik V, Yee KL, Li X, Roecker AJ, Fox SV, Tannenbaum PL, Garson SL, Lepeleire ID, Calder N, Rosen L, Struyk A, Coleman PJ, Herring WJ, Renger JJ, Winrow CJ. Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man. Sci Rep 2016;6:27147. [PMID: 27256922 DOI: 10.1038/srep27147] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 6.3] [Reference Citation Analysis]
68 Ballesta A, Innominato PF, Dallmann R, Rand DA, Lévi FA. Systems Chronotherapeutics. Pharmacol Rev 2017;69:161-99. [PMID: 28351863 DOI: 10.1124/pr.116.013441] [Cited by in Crossref: 148] [Cited by in F6Publishing: 127] [Article Influence: 29.6] [Reference Citation Analysis]
69 Kripke DF. Is suvorexant a better choice than alternative hypnotics? F1000Res 2015;4:456. [PMID: 26594338 DOI: 10.12688/f1000research.6845.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
70 Sutton EL. Profile of suvorexant in the management of insomnia. Drug Des Devel Ther 2015;9:6035-42. [PMID: 26648692 DOI: 10.2147/DDDT.S73224] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
71 Xue T, Wu X, Chen S, Yang Y, Yan Z, Song Z, Zhang W, Zhang J, Chen Z, Wang Z. The efficacy and safety of dual orexin receptor antagonists in primary insomnia: A systematic review and network meta-analysis. Sleep Med Rev 2021;61:101573. [PMID: 34902823 DOI: 10.1016/j.smrv.2021.101573] [Reference Citation Analysis]
72 Black SW, Yamanaka A, Kilduff TS. Challenges in the development of therapeutics for narcolepsy. Prog Neurobiol 2017;152:89-113. [PMID: 26721620 DOI: 10.1016/j.pneurobio.2015.12.002] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 4.6] [Reference Citation Analysis]
73 Riemann D, Krone LB, Wulff K, Nissen C. Sleep, insomnia, and depression. Neuropsychopharmacology 2020;45:74-89. [PMID: 31071719 DOI: 10.1038/s41386-019-0411-y] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 22.3] [Reference Citation Analysis]
74 Flaxer JM, Heyer A, Francois D. Evidenced-Based Review and Evaluation of Clinical Significance: Nonpharmacological and Pharmacological Treatment of Insomnia in the Elderly. Am J Geriatr Psychiatry 2021;29:585-603. [PMID: 33218915 DOI: 10.1016/j.jagp.2020.10.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
75 Stahl SM. Mechanism of action of suvorexant. CNS Spectr 2016;21:215-8. [DOI: 10.1017/s1092852916000225] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
76 Cada DJ, Levien TL, Baker DE. Suvorexant. Hosp Pharm 2015;50:59-71. [PMID: 25684802 DOI: 10.1310/hjp5001-059] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
77 Vermeeren A, Jongen S, Murphy P, Moline M, Filippov G, Pinner K, Perdomo C, Landry I, Majid O, Van Oers ACM, Van Leeuwen CJ, Ramaekers JG, Vuurman EFPM. On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep 2019;42:zsy260. [PMID: 30597112 DOI: 10.1093/sleep/zsy260] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 12.0] [Reference Citation Analysis]